Nanogen Pins Future on New Sales Force, Products After Year of Slumping Revenue | GenomeWeb

Nanogen officials last week pinned the future of their company on the success of a new sales organization, royalties from a company it acquired late last year, and a broadening line of products for the clinical diagnostics market.

“We are a very different company than we used to be,” Robert Saltmarsh, the company’s chief financial officer, told BioArray News last week.

The San Diego-based company reported a 51-percent slide in revenues and an 89-percent increase in net losses for the fourth quarter of 2004.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.